BATTLE (Biomarker-based Approach of Targeted Therapy for Lung Cancer Elimination)

Abstract

The Program BATTLE seeks to establish individualized targeted therapy by prospectively examining patients? tumor biomarker profiles and assigning them to corresponding targeted therapies with the expectation to yield a better clinical outcome. Based on common altered signaling pathways in lung cancer, the BATTLE Program proposes to develop four phase II trials for chemorefractory, advanced NSCLC patients: erlotinib, ZD6474, bexarotene with erlotinib, and sorafenib which target, respectively, EGFR, VEGF / VEGFR, retinoid X receptor and cyclin D1, and Ras / Raf signaling pathways. A novel adaptive randomization statistical design will be applied to the clinical trials to accelerate the identification of best-fit treatment for patients.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Apr 01, 2010
Accession Number
ADA542458

Entities

People

  • Edward Kim
  • Roy Herbst
  • Waunki Hong

Organizations

  • The University of Texas MD Anderson Cancer Center

Tags

DTIC Thesaurus Topics

  • Biological Factors
  • Blood
  • Cancer
  • Carcinoma
  • Cell Physiological Processes
  • Cells
  • Chemistry
  • Epithelial Cells
  • Health Services
  • Medical Personnel
  • Peptide Growth Factors
  • Peptides
  • Proteins

Fields of Study

  • Chemistry

Readers

  • Breast cancer cell signaling and growth regulation.
  • Oncology
  • Regression Analysis.